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Meloxicam (MLX) is a potent non-steroidal anti-inflammatory drug (NSAID) belon-
ging to the enolic acid class. It preferentially inhibits COX-2 and is therefore used for the
treatment of rheumatoid arthritis, osteoarthritis, and other joint diseases (1). Although
MLX is well tolerated orally compared to other NSAIDs, it is associated with ulceroge-
nicity, bellyache and indigestion. This makes administration of MLX unsuitable for pa-
tients with gastric ulcer (2). Oral MLX administration is also associated with drug inter-
actions (3).
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Skin delivery of NSAIDs offers several advantages over
the oral route associated with potential side effects. In the
present investigation, topical gel of meloxicam (MLX) was
formulated using N-methyl pyrrolidone (NMP) as a so-
lubilizer and Carbopol Ultrez 10® as a gelling polymer.
MLX gel was evaluated with respect to different physi-
cochemical parameters such as pH, viscosity and spread-
ability. Irritation potential of MLX gel was studied on rab-
bits. Permeation of MLX gel was studied using freshly
excised rat skin as a membrane. Anti-inflammatory ac-
tivity of MLX gel was studied in rats and compared with
the commercial formulation of piroxicam (Pirox® gel, 0.5 %
m/m). Accelerated stability studies were carried out for
MLX gel for 6 months according to ICH guidelines. MLX
gel was devoid of any skin irritation in rabbits. After 12 h,
cumulative permeation of MLX through excised rat skin
was 3.0 ± 1.2 mg cm–2 with the corresponding flux value
of 0.24 ± 0.09 mg cm–2 h–1. MLX gel exhibited significant-
ly higher anti-inflammatory activity in rats compared to
Pirox® gel. Physicochemically stable and non-irritant
MLX gel was formulated which could deliver significant
amounts of active substance across the skin in vitro and
in vivo to elicit the anti-inflammatory activity.
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Skin delivery represents an attractive alternative to oral administration due to its
numerous advantages, including avoidance of GI irritation, minimum systemic toxicity,
avoidance of hepatic metabolism (4) and provision of steady plasma levels (5). It has
been demonstrated that local administration of NSAIDs promotes analgesia. A small
oral dose of MLX (7.5/15 mg per day), low relative molecular mass (354.1) and excellent
tissue tolerability (6) make MLX a good candidate for topical delivery.
A few investigations are reported on the topical delivery of MLX such as using pen-
etration enhancers (7), hydrogels (8) and microemulsions (9). However, none of these
have established the in vivo pharmacodynamic activity of topically applied MLX.
The specific aims of the present investigation were to formulate a topical gel of
MLX and evaluate it for: (i) different physicochemical properties, (ii) stability as per IGH
guidelines, (iii) skin irritation in rabbits, (iv) permeation across excited rat skin and (v)
anti-inflammatory activity in rats compared to Pirox® gel.
EXPERIMENTAL
Materials
Meloxicam (MLX) was received as a gift sample from Sun Pharmaceutical Indus-
tries Ltd., (India). N-methyl pyrrolidone (NMP) (Pharmasolve® ISP International, USA),
Solutol HS 15 (BASF, India), Transcutol P (Colorcon Asia Pvt. Ltd., India) and Carbopol
Ultrez-10 (Noveon Ltd., India) were also received as gift samples. Pirox® gel, 0.5 %, m/m
(Cipla, India) was purchased from the local pharmacy. Potassium dihydrogen phos-
phate, sodium chloride, Tween 80, propylene glycol, triethanolamine, sodium acetate,
acetic acid and methanol (HPLC grade) were purchased from S.D. Fine Chemicals Ltd.,
(India). Membrane filters (0.22 mm) were purchased from Pall Life Sciences, India. Dou-
bly distilled water was used whenever required.
HPLC analysis of MLX
MLX samples (solubility, skin permeation and stability studies) were quantified by
an in-house HPLC method. The HPLC apparatus consisted of a Jasco PU-2080 Plus In-
telligent HPLC pump equipped with a Jasco UV-2075 Intelligent UV/VIS detector
(Jasco, Japan), a Rheodyne 7725 injector (Rheodyne, USA) and Jasco Borwin Chromatog-
raphy Software (version 1.50).
Isocratic separation was performed using a Spherisorb ODS-2, RP-18 column (4.6 ´
250 mm, 5 mm particle size). The mobile phase comprised methanol/acetate buffer pH
4.5 (45:55, V/V). The flow rate and injection volume used were 1.3 mL min–1 and 20 mL,
respectively. The detection wavelength was set at 363 nm. Under these conditions, MLX
eluted at 8.81 min. The method was linear in the concentration range 0.2–100 mg mL–1;
the LOD and LOQ values were 0.1 and 0.33 mg mL–1, respectively. The method was vali-
dated with respect to inter- and intra-day accuracy and precision as per ICH guidelines
(10). These were determined in terms of the recovery of known amounts of MLX. Re-
peated analysis was performed for three concentrations of MLX (0.25, 10 and 50 mg mL–1)
on the same day to determined intra-day variability and on two different days to estab-
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lish inter-day variability. The relative standard deviation was less than 2 % in both cases.
The mean MLX recovery ranged between 95.3 and 100.9.
Solubility studies
Solubility of MLX was determined in Solutol HS 15 (polyethylene glycol hydroxy-
stearate), N-methyl pyrrolidone, propylene glycol, Transcutol P (diethylene glycol mo-
noethyl ether) and Tween 80 (polyoxyethylene sorbitan monooleate) by the shake flask
method. Briefly, an excess amount of MLX was added to each vial containing 5 mL of the
selected solubilizer. After sealing, the mixtures were subjected to mechanical agitation
for 72 h in an isothermal shaker (Remi, India) at 37 ± 1 °C, followed by centrifugation at
5000 rpm for 15 min and filtration through a membrane filter prior to HPLC analysis.
Formulation of MLX gel
NMP was selected as the vehicle to formulate MLX gel. To formulate 1 % (m/m) gel,
MLX (100 mg) was dissolved in varying amounts of NMP (8–15 %, m/m). Carbopol Ul-
trez 10® was dispersed in water under continuous stirring using an overhead stirrer at
1000 rpm until it yielded a homogenous dispersion. To the MLX solution, Carbopol Ul-
trez 10® dispersion (0.5–1 %, m/m) was added under continuous stirring to yield a ho-
mogenous dispersion, which in turn was neutralized with triethanolamine to obtain a
transparent gel. MLX gel formulations with different amounts of NMP and Carbopol Ul-
trez 10® were formulated. Formulation F4 (Table I) was selected for further studies ba-
sed on its transparency, composition and viscosity.
Evaluation of MLX gel
To determine the drug content, approximately 1 g of MLX gel was weighed in a
100-mL volumetric flask, dissolved in methanol and diluted suitably prior to HPLC
analysis. Viscosity of MLX gel was determined using a Brookfield synchrolectric visco-
meter, model RVT (Brookfield Engineering Laboratories, Inc., USA). To determine the
spredability of MLX gel, 0.5 g of gel was placed within a circle of 1 cm diameter pre-
-marked on a glass plate, over which a second glass plate was placed. A weight of 500 g
was allowed to rest on the upper glass plate for 5 min. The increase in the diameter due
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Table I. Composition of different MLX formulations
Ingredient
Composition (%, m/m)
F1 F2 F3 F4 F5
MLX 1 1 1 1 1
NMP 8 8 8 10 15
Carbopol Ultrez 10® 0.5 0.75 1.0 0.75 0.75
Triethanolamine 1.5 1.75 2.0 1.0 0.5
Water (q. s.) 100 100 100 100 100
to gel spreading was noted. The pH of the 10 % (m/m) gel Equiptronics, India was deter-
mined using a digital pH meter (model Eq-610).
In vitro release studies
In vitro release of MLX gel was studied by the method described by Joshi et al. (11).
Briefly, USP (12) type II apparatus assembled with a small stainless steel disk designed
to hold the gel at the bottom was used for this purpose. Phosphate buffer saline, pH 7.4
(500 mL) equilibrated at 32 ± 0.5 °C was used as medium. MLX gel (2 g) was placed on
the disk in order to ensure that the release surface was as flat as possible. The disk as-
sembly was gently inserted at the bottom of the dissolution vessel and the paddle rota-
tion speed was 25 rpm. Aliquots (2.0 mL) were withdrawn at predetermined intervals
and an equivalent volume of dissolution medium was replaced. The amount of MLX re-
leased was quantified by HPLC analysis.
Stability
Physicochemical stability of MLX gel was studied by subjecting MLX gel samples to
accelerated stability conditions at 25 °C/60 % RH, 30 °C/60 % RH and 40 °C/75 % RH
as per ICH guidelines for a period of 6 months (13). The stability samples (n = 3) were
analyzed for drug content, pH, viscosity and spreadability at 0, 30, 60, 90 and 180 days.
Skin permeation
Skin permeation of MLX was studied using freshly excised hairless abdominal skin
of a male Wistar rat (250 g, 8 weeks), which was housed individually in the animal hou-
se with food and water given ad libitum.
The rat was sacrificed by decapitation. Then, the hairs in the abdominal area of the
animal were carefully cut as short as possible with scissors. In the next step, the skin was
surgically removed, cleaned of muscle, fat or vasculature, and kept at –4 °C for 24 h be-
fore the experiment. Skin samples were mounted on a modified Franz diffusion cell (A =
0.785 cm2) with the dermal skin surface exposed to the receiver phase and the stratum
corneum remained in contact with the donor compartment. The receiver phase used was
phosphate buffer saline, pH 7.4 (10 mL) maintained at 32.0 ± 0.1 °C. MLX gel (0.4 g) was
placed in the donor compartment. Receiver phase (3.0 mL) was withdrawn after 1, 2, 4,
6, 8, and 12 h and an equivalent volume of phosphate buffer added to the receiver com-
partment. The amount of MLX permeated was quantified by HPLC analysis.
Skin irritation
Draize patch test was used on rabbits to evaluate the irritation potential of MLX gel
(14). White New Zealand rabbits of either sex (2.75 ± 0.25 kg, 8–9 weeks) were supplied
by Nicholas Piramal Research Centre, Mumbai, India, and were housed individually in
the animal house with food and water given ad libitum.
Rabbits were divided into three groups (n = 3): group 1 – no application (control),
group 2 – placebo gel without MLX, and group 3 – MLX gel. The back of the rabbits was
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clipped free of hair 24 h prior to the formulation application. Formulation, 0.5 g of each
was applied on the hair-free skin of rabbits by uniform spreading over an area of 4 cm2.
The skin surface was observed for any visible change such as erythema (redness) after
24, 48 and 72 h of the formulation application. The mean erythemal scores were recor-
ded depending on the degree of erythema: no erythema = 0, slight erythema (barely per-
ceptible-light pink) = 1, moderate erythema (dark pink) = 2, moderate to severe erythe-
ma (light red) = 3, and severe erythema (extreme redness) = 4.
Anti-inflammatory activity
Anti-inflammatory effect of topically applied MLX gel was determined in male Wis-
tar rats (210 ± 10 g, 6–8 weeks) by the carrageenean induced paw edema method (15, 16).
For this purpose, rats were divided into three groups (n = 6): group 1 – control (no treat-
ment), group 2 – Pirox® gel, group 3 – MLX gel. They were housed individually in the
animal house with food and water given ad libitum.
Briefly, 30 min after formulation application (0.5 g), rats of both treated groups were
challenged by a subcutaneous injection of a 1 % (m/V) solution of carrageenean in saline
(0.1 mL) into the plantar site of the right hind paw. The paw volume was measured us-
ing a Ugo Basile 7140 plethysmometer (Italy) just before and 1, 2, 3, 4 and 6 h after car-
rageenean administration. The percent inhibition of edema at any time was calculated
for each rat and the difference between MLX gel and Pirox® gel was evaluated statisti-
cally.
Animal care and handling throughout all three experimental procedures described
above were performed in accordance with the CPCSEA guidelines. The experimental
protocols were approved by the Animal Ethical Committee of the Institute of Chemical
Technology, Mumbai, India.
Statistics
Statistical analysis was performed using either a paired Student’s t-test or ANOVA.
RESULTS AND DISCUSSION
Solubility
Solubility studies helped to rationalize the choice of vehicle for gel formulation.
MLX is poorly soluble in water (0.012 mg mL–1, Fig. 1). Among the different solubilizers
screened, MLX exhibited the highest solubility in NMP (135 mg mL–1) and the lowest in
propylene glycol (0.5 mg mL–1). Solubility of MLX in Solutol HS 15, Transcutol P and
Tween 80 was 9.5, 5.4 and 5.0 mg mL–1, respectively. NMP was selected as the vehicle of
choice to formulate MLX gel, based on its solubilization capacity and penetration en-
hancing effect on hydrophilic and hydrophobic actives as well as dermal acceptability
(17, 18).
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Formulation and evaluation of MLX gel
Due to higher concentration of NMP, formulations F4 and F5 were transparent in
appearance compared to F1, F2 and F3 (Table I). Concentration of Carbopol Ultrez-10®
was optimized on the basis of the desired viscosity and spreadability. Carbopol Ultrez-
-10® at a concentration of 0.5 %, m/m produced a gel of fluid consistency, whereas a gel
of high viscosity and lower spreadability was obtained at 1 %, m/m, concentration (data
not shown). Optimum viscosity and spreadability were obtained at Carbopol Ultrez-10®
concentration of 0.75 %, m/m.
Formulations F4 and F5 were transparent in appearance and had the desired viscos-
ity; however, F4 was selected for further studies because of its lower concentration of
NMP. MLX content of the F4 gel was found to be 100.3 ± 1.2 % (n = 3) of the theoretical
value (1 %, m/m). Viscosity of MLX gel was found to be 7.6 ´ 106 mPa s. The pH value of
MLX gel was 7.35 ± 0.01 (n = 3), which is a physiologically acceptable pH and in princi-
ple devoid of any skin irritation.
Spreadability of the topically applied formulation is an important property consid-
ering patient compliance. Formulations with higher spreadability values allow ease of
application and thereby increased surface area available for drug permeation. The in-
crease in MLX gel diameter following the spreadability test was found to be 7.6 cm (n =
3), which is indicative of good spreadability.
In vitro release of MLX gel
In vitro release of the drug from the topical dosage form gives an idea of the amount
of free active drug available for partitioning into the stratum corneum. In vitro release of
MLX from the gel followed first order kinetics (R2 = 0.9584, k = –0.0275 min–1) and corre-
sponding release after 5 and 30 min was 28 and 70 %, respectively. At the end of 60 min,
98.0 % of the applied amount of MLX was released in the dissolution medium (Fig. 2).
Rapid dissolution of MLX gel could be attributed to solubilization of MLX by NMP. This
158















Solubility (mg mL )
–1
Fig. 1. Solubility of MLX in dif-
ferent solubilizers (mean ± SD,
n = 3).
observation suggests that the entire amount of MLX loaded in the gel would be avail-
able for partitioning into the stratum corneum.
Stability
MLX gel subjected to accelerated stability conditions exhibited respectable stability
with respect to drug concentration except at 40 °C/75 % RH (Table II). The MLX assay
values for the samples stored at 25 °C/60 % RH were found to range between 100.0 and
99.4 % after 1, 2, 3 and 6 months of storage and compared to the initial value of 100.3 %
the observed differences in assay values were not statistically significant. The assay val-
ues for the MLX samples stored at 30 °C/60 % RH were found to be between 100.1 and
97.0 % at the same time points as before and the observed differences in assay values
were still not significantly different. However, the assay values for the MLX samples
stored at 40 °C/75 % RH were 95 ± 0.7, 100.3 ± 1.2, 97.9 ± 1.1 and 96.1 ± 0.8 after 1, 2, 3
and 6 months, respectively, indicating loss of MLX after six months. This maximal de-
crease in assay value for the samples stored at 40 °C/78 % RH was aproximately 4 %.
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Fig. 2. In vitro release profile of
MLX from developed gel using
USP paddle over disk method
(mean ± SD, n = 6).
Table II. Chemical stability of MLX in gel during stability testing
Month
MLX content (%)a
25 °C/60 % RH 30 °C/60 % RH 40 °C/75 % RH
0 100.3 ± 1.2b
1 100.0 ± 1.6 100.1 ± 0.5 99.5 ± 0.7
2 99.5 ± 0.2 99.3 ± 1.4 100.3 ± 1.2
3 99.4 ± 0.6 98.5 ± 1.3 97.9 ± 1.1
6 99.8 ± 1.6 97.0 ± 0.5 96.1 ± 0.8b
a Mean ± SD, n = 3.
b Statistically significant difference vs. time zero: p = 0.003.
Skin permeation
Skin permeation of MLX followed first order kinetics (R2 = 0.9947, k = –0.0364 h–1).
The amount of MLX released after 6 and 12 h was 2.2 ± 1.2 and 3.0 ± 1.2 mg cm–2 (Fig. 3).
The corresponding MLX flux was 0.24 ± 0.09 mg cm–2 h–1. About 58 % of the applied
amount of MLX was permeated across the skin. This clearly indicates that the developed
formulation has a great potential to deliver MLX across the skin. Although we did not
attempt to establish the mechanism of MLX permeation through skin, we believe that
the high permeation of MLX from the developed gel is a result of the high concentration
gradient across the skin (due to solubilized MLX) and also due to the permeation en-
hancing effect of NMP. NMP acts by partitioning into the stratum corneum where it al-
ters the barrier function of the membrane (19) and this effect leads to enhancement of
skin permeation of the active drug. Therefore, NMP as a vehicle has played an impor-
tant role for increasing skin permeation of MLX. Considering the oral dose of MLX the
same amount can be delivered topically by using a 2.5-cm2 patch.
Skin irritation
Placebo and MLX gels were devoid of any irritation potential and no edema forma-
tion was observed in any case. Irritation score (primary skin irritation index) for MLX
gel was zero, which indicated its safety and acceptability for topical administration.
Anti-inflammatory activity
In the anti-inflammatory activity test using carrageenean as the phlogistic com-
pound, Pirox® and MLX gel exhibited anti-inflammatory activity up to 6 h (Fig. 4) and
peak activity was observed between 2–6 h for both formulations. MLX gel exhibited sig-
nificantly higher anti-inflammatory activity compared to Pirox® gel (p < 0.05). MLX gel
application resulted in 10 % inhibition at the end of 1 h and it further increased to 30 %
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Fig. 3. In vitro skin permeation of
MLX through rat skin (mean ± SD,
n = 6).
from 2 to 6 h. Inhibition produced by the application of Pirox® gel was 6 and 15 % after 1
and 2 h respectively, and it remained constant up to 6 h. The observed activity difference
between MLX gel and Pirox® gel was around two-fold. Since no topical formulation of
MLX is available on the market, Pirox® gel (0.5 %, m/m piroxicam) was used for com-
parison to study the anti-inflammatory activity. The results confirm the fact that a signi-
ficant amount of MLX was delivered from the gel through skin to induce the anti-in-
flammatory effect. Furthermore, it also proves the penetration enhaning effect of NMP in
vivo, which was not established to date.
CONCLUSIONS
The results present a physicochemically stable and non irritant topical gel of MLX
that could deliver a significant amount of meloxicam across the skin. MLX gel exhibited
two-fold higher anti-inflammatory activity compared to Pirox® gel.
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Fig. 4. Anti-inflammatory studies
on MLX and Pirox® gels in rats
(mean ± SD, n = 6).
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S A @ E T A K
Gel meloksikama za topi~ku primjenu: In vitro i in vivo vrednovanje
YOGESHWAR G. BACHHAV i VANDANA B. PATRAVALE
Primjena nesteroidnih protuupalnih lijekova na ko`u ima nekoliko prednosti nad
peroralnim na~inom primjene uz koju se ve`u odre|ene nuspojave. U radu je opisana
priprava gela meloksikama (MLX) za topi~ku primjenu. U pripravi gela kori{ten je N-
-metil pirolidon (NMP) kao otapalo i Carbopol Ultrez 10® kao polimer za geliranje.
Odre|ivani su razli~iti fizikokemijski parametri kao {to su pH, viskoznost i razmazlji-
vost. Potencijalna iritacija MLX gela testirana je na kuni}ima, a svojstvo permeacije na
svje`im izrescima ko`e {takora. Protuupalno djelovanje pra}eno je na {takorima i uspo-
re|eno s registriranim pripravkom piroksikama (Pirox® gel, 0,5 % m/m). Testovi ubrza-
nog starenja MLX gela ra|eni su tijekom 6 mjeseci prema ICH protokolu. Dobiveni re-
zultati ukazuju da MLX gel nimalo ne iritira ko`u kuni}a. Kumulativna permeacija nakon
12 h bila je 3,0 ± 1,2 mg cm–2, s odgovaraju}em vrijedno{}u fluksa 0,24 ± 0,09 mg cm–2 h–1.
MLX gel pokazao je zna~ajno ja~e protuupalno djelovanje u odnosu na Pirox® gel. Pri-
pravljeni gel je stabilan, ne iritira ko`u, te in vitro i in vivo doprema kroz ko`u ljekovitu
tvar u dovoljnoj koli~ini da ispolji protuupalno djelovanje.
Klju~ne rije~i: meloksikam, gel, stabilnost, permeacija ko`e, iritacija ko`e, protuupalno djelovanje
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